Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24156422 | 0.73 | TDP1 (0.43) | NQO2 | |
| SCHEMBL29170007 | 0.73 | CA2 (0.43) | — | |
| SCHEMBL24156947 | 0.71 | SELL (0.40) | PTPN1NQO2 | |
| SCHEMBL29620726 | 0.68 | — | — | |
| SCHEMBL130102 | 0.68 | — | — | |
| SCHEMBL31320522 | 0.68 | CA12 (0.37) | — | |
| SCHEMBL6008905 | 0.67 | TTR (0.40) | — | |
| SCHEMBL29802594 | 0.67 | TTR (0.40) | — | |
| SCHEMBL31320449 | 0.67 | — | — | |
| SCHEMBL31320511 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024240062-A1 | PYRIDINE-PYRROLO DERIVATIVE AND USE THEREOF IN DRUGS | 广东东阳光药业股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| EP-4168398-A1 | TYK-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-04-26 | — | — | EP | disclosed |
| CN-115715288-A | TYK-2 inhibitors | 百济神州有限公司 | 2023-02-24 | — | — | CN | disclosed |
| WO-2021259208-A1 | TYK-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | PTPN1 371/4885NQO2 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.